ValuEngine upgraded shares of Imprimis Pharmaceuticals (NASDAQ:IMMY) from a strong sell rating to a sell rating in a research report sent to investors on Friday morning.
Shares of Imprimis Pharmaceuticals (NASDAQ IMMY) opened at $1.68 on Friday. Imprimis Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $4.69. The company has a current ratio of 1.67, a quick ratio of 1.28 and a debt-to-equity ratio of 3.94.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last announced its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter. Imprimis Pharmaceuticals had a negative return on equity of 264.98% and a negative net margin of 60.71%.
A number of large investors have recently made changes to their positions in the stock. Granite Investment Partners LLC lifted its position in Imprimis Pharmaceuticals by 46.4% in the fourth quarter. Granite Investment Partners LLC now owns 186,214 shares of the specialty pharmaceutical company’s stock valued at $316,000 after purchasing an additional 59,000 shares during the period. Institutional & Family Asset Management LLC lifted its position in Imprimis Pharmaceuticals by 5.8% in the third quarter. Institutional & Family Asset Management LLC now owns 734,363 shares of the specialty pharmaceutical company’s stock valued at $1,182,000 after purchasing an additional 40,000 shares during the period. Vanguard Group Inc. lifted its position in Imprimis Pharmaceuticals by 78.2% in the second quarter. Vanguard Group Inc. now owns 451,226 shares of the specialty pharmaceutical company’s stock valued at $1,444,000 after purchasing an additional 198,068 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Imprimis Pharmaceuticals by 60.7% in the second quarter. Bank of New York Mellon Corp now owns 35,606 shares of the specialty pharmaceutical company’s stock valued at $114,000 after purchasing an additional 13,455 shares during the period. Hedge funds and other institutional investors own 12.58% of the company’s stock.
WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/06/imprimis-pharmaceuticals-immy-upgraded-by-valuengine-to-sell.html.
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.